Close Menu

stock rating

Analysts revised EPS and revenue estimates as well as target prices following earnings releases on Tuesday by Illumina, Life Technologies, Waters, and Becton Dickinson.

Oppenheimer increased its price target and revenue estimates on Complete Genomics, while Jefferies raised its EPS and price target for Danaher.

An analyst for the investment firm gave PacBio a "Market Perform" rating and Complete Genomics an "Outperform" rating.

Jefferies analyst Jon Wood also raised his price target on the firm's stock to $15.50 from $13, following a presentation by Complete Genomics CEO Clifford Reid at a biotech conference.

The investment firm lowered its estimates from levels predicted last week to reflect lost consumables sales on its older next-gen sequencing platforms and softer microarray consumables sales sequentially.

Analyst Dan Leonard said growth will be driven by what he expects to be record-breaking sales of Illumina's next-generation sequencing platforms, including its HiSeq, in the first and second quarters of 2011.

Macquarie Capital analyst Dane Leone gave Genomic Health an "Outperform" rating and a $34 price target, and Myriad a "Neutral" rating with a $20 share price.

Brian Weinstein expressed concern about competition in the HPV space and a stock that has tracked the overall market since 2007, but gave a thumbs up to the $355 acquisition of Cellestis.

An analyst at the investment firm said that the expanded production of Illumina's HiSeq sequencing platform is expected to result in sequential revenue growth in the first and second quarters of 2011, but revenue growth will likely abate in the third quarter.

The new revenue estimates come amid concerns about the effect of the Japanese earthquake, competition in the next-generation sequencing space, and government funding on the company's business.

Pages

The Washington Post reports that Herbert Tabor, who worked at the US National Institutes of Health for 77 years, has died at 101.

The World Bank is seeking approval for a $12 billion plan to provide low-income nations with funds to procure SARS-CoV-2 vaccines, according to Reuters.

Science writes that public health officials and others are debating whether cycle threshold values should be included on SARS-CoV-2 results.

In Nucleic Acids Research this week: online database of SARS-CoV-2 protein structures, atlas of the human brain, and more.